Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

mHealth fysisk aktivitetsintervensjon for unge kreftoverlevere (AYA-PACT)

17. november 2026 oppdatert av: AHS Cancer Control Alberta

Ungdom og unge voksne blir fysisk aktive etter kreftprøven

In this randomized controlled trial the investigators will determine whether a mobile health intervention can increase physical activity levels in AYA cancer survivors over a one year period. The investigators will recruit 320 cancer survivors in Alberta who were diagnosed with a first cancer between the ages of 15 to 39 years and are within one year of treatment completion. Participants will be randomized into either the control group (educational information) or the intervention group (educational information; personalized physical activity plan; activity tracker watch; access to a private, online survivor community; motivational text messages and check-in calls/e-mails). All participants will complete fitness testing and questionnaires at baseline, 6 months and 12 months. A final measurement at 24 months will test long-term effectiveness.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Background:

There is a need for adolescent and young adult (AYA) cancer research because the number of new cancers in young people is increasing and the survivor population is growing. Interventions that try to reduce problems that affect people after cancer are particularly important since its treatments can have negative effects on survivors' physical and mental health even decades after diagnosis.

Aim:

Given the many positive effects of physical activity (e.g. improved fitness and quality of life), the study aims to encourage AYA cancer survivors to be more physically active as they shift from treatment to survivorship care. The main goal of this study is to see if a home-based, mobile health (mHealth) physical activity intervention can increase physical activity levels by at least 90 minutes/week compared to baseline in AYA cancer survivors.

Methods:

The investigators will conduct a two-center randomized controlled trial of 320 AYA cancer survivors. Participants (N=320) will be Albertan residents, diagnosed with a first cancer between the ages of 15 and 39 years, and within one year of cancer treatment completion. At the start of the study, participants will complete fitness testing and questionnaires. Participants will then be randomly put into either a control or intervention group. The control group will receive educational information only. The intervention group will also receive a personalized physical activity plan, an activity tracker watch, access to a private, online survivor community, motivational text messages and check-in calls/e-mails. Fitness testing and questionnaires will be repeated at 6 and 12 months to see if the intervention increased physical activity levels and improved health outcomes among the participants in the intervention group compared to controls. A final measurement at 24 months will test long-term use.

Studietype

Intervensjonell

Registrering (Faktiske)

287

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Alberta
      • Calgary, Alberta, Canada, T2N5G2
        • Arthur J.E. Child Comprehensive Cancer Centre
      • Edmonton, Alberta, Canada, T6G2H9
        • University of Alberta

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

15 år til 39 år (Barn, Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Lives in Alberta
  • Diagnosed with invasive malignancy in Alberta
  • Completed active cancer directed therapy (cytotoxic chemotherapy, radiation therapy and/or definitive surgical intervention) in the last 12 months, except for "maintenance" therapy to prevent recurrences
  • Have the ability to read, write and speak English
  • Have access to the Internet on at least a weekly basis
  • Have a mobile phone with a text messaging plan
  • Willing to be randomized to either arm.

Exclusion Criteria:

  • Health problems which preclude the ability to walk for physical activity, as measured by the Physical Activity Readiness Questionnaire (PAR-Q)
  • Currently pregnant or planning to become pregnant within the next 6 months
  • Currently taking part in > 300 minutes/week of moderate-to-vigorous intensity physical activity on a regular basis

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Støttende omsorg
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: mHealth Physical Activity Intervention

The intervention arm will receive a 12 month mobile health (mHealth) physical activity intervention with a goal of increasing their moderate-vigorous intensity physical activity levels by 90 minutes per week above baseline.

The intervention includes a physical activity prescription, a Polar activity tracker watch, access to a private AYA cancer survivor community through the Polar Flow community platform, mHealth nudges and surveys via text messaging, and regular phone or email contact from study staff.

Ingen inngripen: Control

Controls received "standard of care" from their medical team and were not provided with any physical activity guidance.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Changes in weekly minutes of moderate-vigorous intensity physical activity
Tidsramme: Baseline to 12 months

Measured by ActiGraph

Baseline to 12 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Changes in weekly minutes of moderate-vigorous intensity physical activity
Tidsramme: Baseline to 6 months and 24 months.

Measured by ActiGraph

Baseline to 6 months and 24 months.
Changes in weekly minutes of sleep
Tidsramme: Baseline, 6 months, 12 months, 24 months

Measured by ActiGraph

Baseline, 6 months, 12 months, 24 months
Changes in weekly minutes of sedentary time
Tidsramme: Baseline, 6 months,12 months, 24 months

Measured by ActiGraph

Baseline, 6 months,12 months, 24 months
Changes in moderate-vigorous physical activity using the self-administered Past Year Total Physical Activity Questionnaire (PYTPAQ).
Tidsramme: Baseline, 12 months, 24 months.

Met-Hours per week and hours per week of moderate-vigorous physical activity

Baseline, 12 months, 24 months.
Changes in the Pittsburgh Sleep Quality Index (PSQI) Global Sleep Quality Score
Tidsramme: Baseline, 6 months,12 months

Global score range is 0 to 23 where higher scores indicate worse sleep quality

Baseline, 6 months,12 months
Changes in weight
Tidsramme: Baseline, 6 months,12 months

Measured in kilograms

Baseline, 6 months,12 months
Changes in body mass index (BMI)
Tidsramme: Baseline, 6 months,12 months

Measured by combining height (meters) and weight (kilograms) and reported in kg/m2

Baseline, 6 months,12 months
Changes in waist and hip circumference
Tidsramme: Baseline, 6 months,12 months

Measured in centimeters

Baseline, 6 months,12 months
Changes in cardiorespiratory fitness
Tidsramme: Baseline, 6 months,12 months

Measured by peak oxygen consumption in relative (ml/kg/min) values using the modified Bruce protocol treadmill test with direct measures of gas exchange and ventilation

Baseline, 6 months,12 months
Changes in cardiorespiratory fitness
Tidsramme: Baseline, 6 months,12 months

Measured by peak oxygen consumption in absolute (L/min) values using the modified Bruce protocol treadmill test with direct measures of gas exchange and ventilation

Baseline, 6 months,12 months
Changes in grip strength
Tidsramme: Baseline, 6 months,12 months

Measured in kilograms using a hand dynamometer

Baseline, 6 months,12 months
Changes in upper body muscular strength
Tidsramme: Baseline, 6 months,12 months

Measured in kilograms using an 8-10 repetition maximum (RM) chest press test used to predict 1-RM

Baseline, 6 months,12 months
Changes in upper body muscular endurance
Tidsramme: Baseline, 6 months,12 months

Measured in kilograms using the maximum number of chest press repetitions completed at 50% of estimated 1-RM

Baseline, 6 months,12 months
Changes in lower body muscular strength
Tidsramme: Baseline, 6 months,12 months

Measured in kilograms using an 8-10 repetition maximum (RM) leg press test used to predict 1-RM

Baseline, 6 months,12 months
Changes in lower body muscular endurance
Tidsramme: Baseline, 6 months,12 months

Measured in kilograms using the maximum number of leg press repetitions completed at 70% of estimated 1-RM

Baseline, 6 months,12 months
Changes in frailty
Tidsramme: Baseline, 6 months,12 months

Defined according to the Fried phenotype which takes into account low lean muscle mass, exhaustion, low energy expenditure, walking limitations, and weakness

Baseline, 6 months,12 months
Changes in the Short Form 36 (SF-36) Mental Health Component subscale
Tidsramme: Baseline, 6 months,12 months

Score range is from 0 to 100 where higher scores indicate better mental health

Baseline, 6 months,12 months
Changes in the Short Form 36 (SF-36) Physical Health Component subscale
Tidsramme: Baseline, 6 months,12 months

Score range is from 0 to 100 where higher scores indicate better physical health

Baseline, 6 months,12 months
Changes in the Short Form 36 (SF-36) Physical Functioning subscale
Tidsramme: Baseline, 6 months,12 months

Score range is from 0 to 100 where higher scores indicate higher functioning

Baseline, 6 months,12 months
Changes in the Short Form 36 (SF-36) Role-physical subscale
Tidsramme: Baseline, 6 months,12 months

Score range is from 0 to 100 where higher scores indicate higher functioning

Baseline, 6 months,12 months
Changes in the Short Form 36 (SF-36) Bodily Pain subscale
Tidsramme: Baseline, 6 months,12 months

Score range is from 0 to 100 where higher scores indicate less pain

Baseline, 6 months,12 months
Changes in the Short Form 36 (SF-36) General Health subscale
Tidsramme: Baseline, 6 months,12 months

Score range is from 0 to 100 where higher scores indicate better health

Baseline, 6 months,12 months
Changes in the Short Form 36 (SF-36) Vitality subscale
Tidsramme: Baseline, 6 months,12 months

Score range is from 0 to 100 where higher scores indicate higher vitality

Baseline, 6 months,12 months
Changes in the Short Form 36 (SF-36) Social Functioning subscale
Tidsramme: Baseline, 6 months,12 months

Score range is from 0 to 100 where higher scores indicate higher functioning

Baseline, 6 months,12 months
Changes in the Short Form 36 (SF-36) Role-emotional subscale
Tidsramme: Baseline, 6 months,12 months

Score range is from 0 to 100 where higher scores indicate higher functioning

Baseline, 6 months,12 months
Changes in the Short Form 36 Mental Health subscale
Tidsramme: Baseline, 6 months,12 months

Score range is from 0 to 100 where higher scores indicate better mental health

Baseline, 6 months,12 months
Changes in the Cancer Distress Scales for AYAs Impact of Cancer subscale
Tidsramme: Baseline, 6 months,12 months

Scores range from 0 to 100 where higher scores indicate more distress

Baseline, 6 months,12 months
Changes in the Cancer Distress Scales for AYAs Physical subscale
Tidsramme: Baseline, 6 months,12 months

Scores range from 0 to 100 where higher scores indicate more distress

Baseline, 6 months,12 months
Changes in the Cancer Distress Scales for AYAs Emotional subscale
Tidsramme: Baseline, 6 months,12 months

Scores range from 0 to 100 where higher scores indicate more distress

Baseline, 6 months,12 months
Changes in the Cancer Distress Scales for AYAs Cognitive subscale
Tidsramme: Baseline, 6 months,12 months

Scores range from 0 to 100 where higher scores indicate more distress

Baseline, 6 months,12 months
Changes in the Cancer Distress Scales for AYAs Cancer Worry subscale
Tidsramme: Baseline, 6 months,12 months

Scores range from 0 to 100 where higher scores indicate more distress

Baseline, 6 months,12 months
Changes in the Functional Assessment of Cancer Therapy Cognitive Function Perceived Cognitive Impairment subscale
Tidsramme: Baseline, 6 months,12 months

Score range is from 0 to 72. Higher scores indicate better quality of life.

Baseline, 6 months,12 months
Changes in the Functional Assessment of Cancer Therapy Cognitive Function (FACT-Cog) Comments From Others subscale
Tidsramme: Baseline, 6 months,12 months

Score range is from 0 to 16 where higher scores indicate better quality of life.

Baseline, 6 months,12 months
Changes in the Functional Assessment of Cancer Therapy Cognitive Function (FACT-Cog) Perceived Cognitive Abilities subscale
Tidsramme: Baseline, 6 months,12 months

Score range is from 0 to 36 where higher scores indicate poorer cognition

Baseline, 6 months,12 months
Changes in the Functional Assessment of Cancer Therapy Cognitive Function (FACT-Cog) Impact on Quality of Life subscale
Tidsramme: Baseline, 6 months,12 months

Score range is from 0 to 16 where higher scores indicate better quality of life.

Baseline, 6 months,12 months
Changes in the Functional Assessment of Cancer Therapy Fatigue (FACT-F)
Tidsramme: Baseline, 6 months,12 months

Score range is from 0 to 52 where higher scores indicate better quality of life.

Baseline, 6 months,12 months
Changes in the Comprehensive Score for Financial Toxicity (COST)
Tidsramme: Baseline, 6 months,12 months

Score range is from 0 to 44 where higher scores indicate better financial wellbeing

Baseline, 6 months,12 months
Changes in fear of cancer recurrence - short form (FCRI-SF)
Tidsramme: Baseline, 6 months, 12 months

Score range is from 0 - 36 where higher scores indicate greater fear of recurrence severity.

Baseline, 6 months, 12 months
Changes in Sedentary Behaviour using a 7 day Sedentary Recall
Tidsramme: Baseline, 6 months, 12 months.

Hours of sitting during the week and on weekends for the following categories: (1) traveling to work, (2) at work or school, (3) watching television, (4) using a computer, and (5) leisure time not including television.

Baseline, 6 months, 12 months.
Changes in environmental barriers that prevent or limit walking and cycling where a person lives or works - PANES Questionnaire
Tidsramme: Baseline, 6 months, 12 months.

Score range is from 1 to 4 with higher values indicating greater environmental support for physical activity.

Baseline, 6 months, 12 months.
Changes in Exercise Self-Efficacy - Subscale (FITNET Questionnaire)
Tidsramme: Baseline, 6 months, 12 months

Range of scores from 11 to 55 with higher scores indicated higher self-efficacy.

Baseline, 6 months, 12 months
Changes in Social Support from Family and Friends related to Exercise - Subscale (FITNET Questionnaire)
Tidsramme: Baseline, 6 months, 12 months.

Range of scores from 10 to 50 with higher scores indicating more support.

Baseline, 6 months, 12 months.
Changes in Self-Monitoring related to setting exercise goals and planning exercise activities - Subscale (FITNET Questionnaire)
Tidsramme: Baseline, 6 months, 12 months.

Range of scores from 12 to 60 with higher scores indicating more self-monitoring.

Baseline, 6 months, 12 months.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Studieleder: Miranda Fidler-Benaoudia, PhD, Cancer Care Alberta
  • Hovedetterforsker: Christine Friedenreich, PhD, Cancer Care Alberta

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

27. september 2021

Primær fullføring (Faktiske)

16. juli 2026

Studiet fullført (Antatt)

1. mai 2027

Datoer for studieregistrering

Først innsendt

9. februar 2021

Først innsendt som oppfylte QC-kriteriene

19. februar 2021

Først lagt ut (Faktiske)

21. februar 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

17. november 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere